Palmetto's Loss of Jurisdiction E Medicare Contract Raises Questions About Fate of MolDx Program | GenomeWeb

Originally published Oct. 12.

Medicare contractor Palmetto GBA has recently been outbid in its contract to administer services for the Centers for Medicare & Medicaid Services in several US states — a turn of events that has labs and molecular diagnostic companies wondering about the future of Palmetto's MolDx program, an effort to track utilization of molecular diagnostics and set reimbursement rates based on the value these tests provide to patient care.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."